Tyrosine kinase inhibitors in the treatment of systemic mastocytosis
C Ustun, DL DeRemer, C Akin - Leukemia research, 2011 - Elsevier
Systemic mastocytosis (SM) is a heterogeneous disease, vast majority of these patients
have a gain of function mutation in the gene encoding the tyrosine kinase KIT (KITD816V). A
small subset of SM patients with KITD816V mutation require cytoreductive therapy. In these
patients, tyrosine kinase inhibitors (TKIs) have been actively investigated over the last
decade because of codon 816 KIT mutations causing constitutive activation of tyrosine
kinase activity of the molecule. The main question has been whether the success story with …
have a gain of function mutation in the gene encoding the tyrosine kinase KIT (KITD816V). A
small subset of SM patients with KITD816V mutation require cytoreductive therapy. In these
patients, tyrosine kinase inhibitors (TKIs) have been actively investigated over the last
decade because of codon 816 KIT mutations causing constitutive activation of tyrosine
kinase activity of the molecule. The main question has been whether the success story with …